X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5173) 5173
Book Chapter (29) 29
Dissertation (6) 6
Publication (4) 4
Government Document (3) 3
Book / eBook (2) 2
Newspaper Article (2) 2
Streaming Video (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2810) 2810
immunotherapy (2327) 2327
animals (1814) 1814
oncology (1786) 1786
immunology (1768) 1768
ctla-4 (1601) 1601
cancer (1569) 1569
melanoma (1283) 1283
ctla-4 blockade (1161) 1161
mice (1142) 1142
female (1107) 1107
ipilimumab (1071) 1071
ctla-4 antigen (1036) 1036
lymphocytes (1018) 1018
male (991) 991
ctla-4 protein (966) 966
t cells (906) 906
lymphocytes t (875) 875
tumors (836) 836
immune checkpoint (780) 780
expression (746) 746
antigens (736) 736
pd-1 (734) 734
antibodies, monoclonal - therapeutic use (690) 690
metastatic melanoma (678) 678
ctla-4 antigen - immunology (652) 652
blockade (651) 651
ctla-4 antigen - antagonists & inhibitors (648) 648
care and treatment (624) 624
middle aged (587) 587
cytotoxicity (581) 581
t-lymphocytes - immunology (581) 581
immunotherapy - methods (553) 553
t-cells (549) 549
nivolumab (532) 532
pd-1 blockade (528) 528
neoplasms - immunology (527) 527
antigens, cd (523) 523
abatacept (513) 513
dendritic cells (508) 508
regulatory t-cells (503) 503
metastasis (498) 498
research (492) 492
activation (485) 485
immune system (481) 481
adult (477) 477
pd-1 protein (477) 477
medicine, research & experimental (476) 476
apoptosis (471) 471
patients (450) 450
programmed cell death 1 receptor - antagonists & inhibitors (446) 446
chemotherapy (444) 444
mice, inbred c57bl (439) 439
aged (437) 437
immune response (434) 434
therapy (434) 434
melanoma - drug therapy (395) 395
chemical and pharmacologic phenomena (394) 394
cancer therapies (390) 390
immunoconjugates (390) 390
neoplasms - therapy (389) 389
clinical trials (385) 385
health aspects (384) 384
analysis (376) 376
review (368) 368
autoimmunity (364) 364
antibodies (363) 363
survival (363) 363
cell biology (361) 361
t-lymphocytes, regulatory - immunology (360) 360
antineoplastic agents - therapeutic use (355) 355
treatment outcome (354) 354
antitumor immunity (350) 350
pembrolizumab (347) 347
t cell receptors (345) 345
in-vivo (343) 343
programmed cell death 1 receptor - immunology (342) 342
mice, inbred balb c (341) 341
antigens, cd - immunology (338) 338
cytokines (337) 337
pd-l1 (336) 336
antigens, differentiation - immunology (331) 331
metastases (326) 326
gene expression (324) 324
ligands (324) 324
biomarkers (323) 323
mutation (322) 322
open-label (319) 319
lymphocyte activation (318) 318
melanoma - immunology (317) 317
multidisciplinary sciences (314) 314
ctla-4 antigen - metabolism (305) 305
cd28 (304) 304
monoclonal antibodies (302) 302
immunity (300) 300
pd-l1 protein (294) 294
cd8-positive t-lymphocytes - immunology (293) 293
flow cytometry (292) 292
proteins (290) 290
responses (283) 283
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5161) 5161
French (31) 31
German (31) 31
Japanese (14) 14
Chinese (5) 5
Polish (5) 5
Portuguese (4) 4
Spanish (3) 3
Hebrew (1) 1
Hungarian (1) 1
Italian (1) 1
Korean (1) 1
Russian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science (American Association for the Advancement of Science), ISSN 1095-9203, 2018, Volume 362, Issue 6411, pp. eaar3593 - 197
Programmed cell death protein–1 (PD-1) and programmed cell death ligand–1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in multiple cancers, yet not all patients respond... 
CELL LUNG-CANCER | MISMATCH-REPAIR DEFICIENCY | MUTATIONAL PROCESSES | METASTATIC MELANOMA | CTLA-4 BLOCKADE | MULTIDISCIPLINARY SCIENCES | COPY NUMBER | PROGRAMMED DEATH LIGAND-1 | SEQUENCING DATA | CLINICAL-RESPONSE | SOMATIC MUTATIONS | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Transcriptome | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Genetic Markers | Cell Cycle Checkpoints | Neoplasms - therapy | Neoplasms - genetics | Antineoplastic Agents, Immunological - therapeutic use | Immunotherapy | Inflammation - genetics | T-Lymphocytes - immunology | Tumor Burden - genetics | Biomarkers, Tumor - genetics | Mutation | Molecular Targeted Therapy - methods | Cell receptors | Physiological aspects | Diagnosis | Biological markers | Identification and classification | Methods | Cancer | PD-1 protein | Genomics | Clinical trials | Genomes | Biology | Lymphocytes T | Microsatellite instability | Subgroups | Anticancer properties | Proteins | Cell activation | Pembrolizumab | Databases | Antigenicity | Lymphocytes | Deoxyribonucleic acid--DNA | Medical research | Stability | Mortality | Melanoma | Data processing | Inflammation | Gene expression | Patients | Immune checkpoint | Cell death | Correlation analysis | PD-L1 protein | Monoclonal antibodies | Biomarkers | Ligands | Antitumor activity | Cutoffs | Solid tumors | Apoptosis | Tumors
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2019, Volume 116, Issue 20, pp. 9999 - 10008
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 18, pp. 1749 - 1755
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2018, Volume 359, Issue 6382, pp. 1350 - 1355
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2189 - 2199
Journal Article
Cancer discovery, ISSN 2159-8290, 2017, Volume 7, Issue 3, pp. 264 - 276
... blockade with anti-PD-1 or anti-PD-1/anti-CTLA-4 antibodies. Analyses of matched pretreatment and resistant tumors identified genomic changes resulting in loss of 7 to 18 putative mutation-associated neoantigens in resistant clones... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | ONCOLOGY | PD-1 BLOCKADE | COLORECTAL-CANCER | PANCREATIC-CANCER | COPY NUMBER | RESISTANCE | MUTATIONS | SEQUENCING DATA | TUMOR PURITY | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Ipilimumab - pharmacology | Immunotherapy | Ipilimumab - therapeutic use | Janus Kinase 1 - genetics | Adult | Female | Receptors, Antigen, T-Cell - immunology | Cell Cycle Checkpoints - immunology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Receptors, Antigen, T-Cell - metabolism | Antigens, Neoplasm - immunology | Carcinoma, Non-Small-Cell Lung - genetics | Antibodies, Monoclonal - pharmacology | Janus Kinase 2 - genetics | CTLA-4 Antigen - genetics | Drug Resistance, Neoplasm - immunology | Lung Neoplasms - therapy | CTLA-4 Antigen - immunology | Antineoplastic Agents, Immunological - pharmacology | Carcinoma, Non-Small-Cell Lung - immunology | Carcinoma, Non-Small-Cell Lung - therapy | Drug Resistance, Neoplasm - genetics | Lung Neoplasms - immunology | Antineoplastic Agents, Immunological - therapeutic use | Cell Cycle Checkpoints - drug effects | Receptors, Antigen, T-Cell - genetics | Mutation | Programmed Cell Death 1 Receptor - immunology | Programmed Cell Death 1 Receptor - genetics | Cohort Studies
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2015, Volume 350, Issue 6264, pp. 1079 - 1084
Journal Article